Trials / Completed
CompletedNCT01380184
Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)
A Study to Assess the Pharmacokinetics of Ridaforolimus in Chinese Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Part 1 of the study will assess the pharmacokinetics, safety, and tolerability of ridaforolimus (MK-8669) after administration of single and multiple 40 mg doses in Chinese participants with advanced cancer. Part 2 of the study is optional; participants can continue to receive the study treatment in a weekly regimen of daily oral doses of ridaforolimus 40 mg for five consecutive days followed by two days off-treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ridaforolimus | 4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg) |
Timeline
- Start date
- 2011-07-05
- Primary completion
- 2011-10-20
- Completion
- 2012-04-05
- First posted
- 2011-06-27
- Last updated
- 2019-04-19
- Results posted
- 2019-04-19
Source: ClinicalTrials.gov record NCT01380184. Inclusion in this directory is not an endorsement.